The largest blog for reading the latest medical research on all disease, the prevention and its treatment . Pulled from variety of sources

Wednesday, March 29, 2017

MarketWatch : reported that Tesaro won’t reveal price of its ovarian cancer drug. But it’ll likely be near $14,000 a month

See: Tesaro stock rises 6% on news that its ovarian Cancer addiction was approved by the FDAHow Close Are We to a World Without Cancer? That could change soon: AstraZeneca announced early Tuesday that the FDA was reviewing Lynparza for maintenance in relapsed ovarian cancer patients. When Tesaro Inc. announced Monday afternoon that the U.S. Food and Drug Administration had approved its ovarian cancer drug, the company said it would wait to announce the drug's price until Zejula launched, in late April. In contrast with Zejula, both Rubraca and Lynparza are limited to patients with a BRCA mutation, which leads to higher risk of ovarian cancer. The delay until April could be a public relations strategy, Loncar said, to avoid the drug's price becoming the focal point of media coverage.


Drug to treat advanced ovarian cancer gets early FDA approval


Drug to treat advanced ovarian cancer gets early FDA approval
Along with ovarian cancer patients, the clinical trial included those with fallopian tube peritoneal cancers. "Each year over 14,000 women die of ovarian cancer," the highest for any gynecologic cancer, he said. About 22,000 women develop ovarian cancer annually in the United States. BRCA mutations predispose carriers to breast, ovarian and other cancers. For women without BRCA mutations, progression-free survival was 9.3 months compared with 3.9 months for those on placebo.

Study finds 12 genetic variants that raise the risk of ovarian cancer

A large genetic study has identified 12 new variants commonly associated with the risk of epithelial Ovarian cancer. Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer. The genes we inherit affect our chances of developing ovarian cancer, and a new genomic study identifies 12 genetic variants associated with the risk. Ovarian cancer is a common form of cancer and a leading cause of cancer death among women. "We know that a woman's genetic makeup accounts for about one third of her risk of developing ovarian cancer.


collected by :Lucy William

To follow all the new news about Disease !!! All you need to know about all kinds of diseases

No comments:

Post a Comment